Impact of Sugammadex Versus Neostigmine Reversal on Postoperative Recovery Time in Patients With Obstructive Sleep Apnea Undergoing Bariatric Surgery: A Double-Blind, Randomized Controlled Trial
Authors' conclusion
No difference was observed in OR discharge time in morbidly obese patients with OSA when sugammadex was administered instead of neostigmine.
Study context
- Population
- Morbidly obese adults with obstructive sleep apnea (OSA) undergoing elective bariatric surgery under GA
- Participants
- 120 adults
- Comparison
- Sugammadex vs neostigmine for NMB reversal
- Sugammadexn = 60
- Neostigminen = 60reference
- Primary endpoint
- Time from administration of NMBD reversal agent to discharge from the OR
Methodological detailsprospective, double-blinded, superiority, 2 parallel groups
- Prospective
- Double-blinded
- Superiority
- 2 parallel groups
Primary result
As reported in the abstract
Time from NMBD reversal agent administration to OR discharge
- Treatment effect estimate
- −0.5 (bootstrapped 95% CI −2.5 to 3)
Secondary outcomes
Time to eye opening to command, time to extubation and other secondary outcomes
- No differences observed
Safety
Postoperative complications
- No differences observed
Original publication
Impact of Sugammadex Versus Neostigmine Reversal on Postoperative Recovery Time in Patients With Obstructive Sleep Apnea Undergoing Bariatric Surgery: A Double-Blind, Randomized Controlled Trial. Anesth Analg. Published 7 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →